Congenital Adrenal Hyperplasia Study
Protocol: STUDY00004354
Full Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
Description
This study enrolls adults with Congenital Adrenal Hyperplasia. The purpose of this study is to see if an investigational drug called tildacerfont is safe and effective in reducing the level of certain hormones in your body.


You will be in this study for about 66 weeks, and during that time you will have 12 study visits to the study site and telephone calls as needed. Please contact the research team for more details about this study. Study takes place at Diabetes and Endocrinology Research Center of WNY 1000 Youngs Rd Suite 105 Williamsville NY 14221.

Technical Description

To evaluate the effect of tildacerfont in reducing A4 in subjects with CAH over 12 weeks
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
Adults ages 18-55.
Has a documented historical diagnosis of classic Congenital Adrenal Hyperplasia (CAH)
Age Group: Adults
Principal Investigator: AJAY CHAUDHURI
Contact(s)
Arsalan Mustafa
arsalanm@buffalo.edu
+1 716-548-9493
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.